Iovance Biotherapeutics Inc

The fair value estimate for Iovance Biotherapeutics has been raised to US$12.80 per share from US$10.00, according to Simply Wall St. The revision reflects stronger expectations for the Amtagvi launch, margin trends and upcoming data, with the revenue growth assumption shifting from 43.38% to 45.57% and the net profit margin assumption moving from 9.50% to 12.09%. H.C. Wainwright lifted its price target to US$20 from US$9, citing FY26 total revenue guidance of US$410m to US$420m tied to U.S. demand for Amtagvi and Proleukin, while Wells Fargo moved to US$18 from US$14 and Goldman Sachs pointed to an inflection in the Amtagvi launch and easing logistical challenges. Barclays flagged durability in second line lung cancer for lifileucel ahead of IOV-LUN-202 data, while UBS, which raised its target to US$7 from US$4 and remains Neutral, noted that a strong Amtagvi quarter and gross margin of 56% came alongside a 74% rally in the stock. The valuation model's future P/E multiple changed from 75.55x to 72.80x and the discount rate moved from 7.47% to 7.50%.

The analyst fair value estimate for Iovance Biotherapeutics has been raised from US$9.33 to US$10.00 per share, with recent price targets clustering in the US$10 to US$15 range. Barclays, TD Cowen and Mizuho have all lifted their price targets, with the upper end of recent moves reaching US$15, citing Amtagvi revenue trends, margin progression and the potential impact of upcoming data such as IOV-LUN-202. UBS pointed to Amtagvi revenue of US$91m and a 56% gross margin in Q2, supported by manufacturing efficiency and ATC performance, though it kept a Neutral rating and flagged that a 74% post Q2 rally has already reflected much of the near term upside. Barclays cited its physician survey and sees durability as a key differentiator for lifileucel in second line lung cancer ahead of the IOV-LUN-202 data in Q4, which it views as an important potential catalyst. The updated model also shows the projected net profit margin moving from 7.99% to about 9.50% and the future P/E multiple adjusting from 83.56x to about 75.55x.

Iovance Biotherapeutics reported a narrower-than-expected second-quarter 2026 loss and revenue that beat estimates, driven by strong sales of its TIL therapy Amtagvi, sending shares up 43% to a 52-week high. The company posted a loss of 11 cents per share, compared with the Zacks Consensus Estimate of a 17-cent loss, while total revenues rose 66% year over year to $99.3 million, exceeding the consensus of $87.3 million and management's own guidance of $86-$88 million. Amtagvi sales surged 68% year over year to $90.7 million, well above the $79 million consensus, and Proleukin sales increased 46% to $8.6 million. Gross margin improved to 56% from 41% in the prior quarter, and the company ended the period with approximately $304 million in cash, which it expects will fund operations into the second half of 2028. Management is reviewing its full-year 2026 revenue guidance of $350-$370 million and plans to provide an update in the third quarter amid strong demand trends.

ClearOne, NeOnc Technologies, Iovance Biotherapeutics, and Ensysce Biosciences each reported significant clinical, regulatory, or financial developments. ClearOne moved closer to completing its acquisition of Cortigent, a neurotechnology subsidiary of Vivani Medical, after majority shareholder First Finance Ltd., which controls approximately 61.3% of voting power, approved the transaction and the issuance of 12.5 million shares. NeOnc Technologies is approaching topline Phase 2a data from its fully enrolled NEO100-01 study and has expanded internationally with a second IND authorization from Abu Dhabi for recurrent high-grade gliomas. Iovance Biotherapeutics reported record second-quarter 2026 revenue of approximately $99.3 million, a 66% year-over-year increase driven by its FDA-approved TIL therapy Amtagvi, and is reviewing its 2026 revenue guidance of $350 million to $370 million. Ensysce Biosciences acquired privately held Cy Biopharma, adding the clinical-stage neuroplastogenic therapy CY200 for Complex Regional Pain Syndrome Type 1, and secured financing that could total up to $77 million, including $17.1 million in cash and a $21.5 million private placement led by Ally Bridge Group.

Apollomics shares surged over 22% on Wednesday after the company regained compliance with Nasdaq's Market Value of Listed Securities requirement. The clinical-stage firm, whose lead program is the c-Met inhibitor Vebreltinib for non-small cell lung cancer, was notified on July 8 that the matter had been closed. Other notable movers included Iovance Biotherapeutics, up more than 20% ahead of its second-quarter report, where Amtagvi revenue is expected between $79 million and $81 million, about 23% higher than in the fourth quarter of 2025. AVITA Medical rose over 17% before its own second-quarter update, while Annexon gained more than 17% in anticipation of a presentation at the American Society of Retina Specialists meeting and upcoming pivotal data from its Phase 3 ARCHER II trial in geographic atrophy. Veradermics climbed over 12% after reporting positive Phase 2 results for its oral minoxidil formulation VDPHL01 in female pattern hair loss, with 88.9% of once-daily patients reporting improved or much improved outcomes by month six.

Iovance Biotherapeutics shares have soared 74% this year, trading near $5 with an average analyst price target of $8.80. The company's key product, Amtagvi, an approved melanoma therapy made from patients' own cells, generated $71.4 million in first-quarter revenue, a 45% year-over-year increase. Iovance is expanding Amtagvi's reach, having gained approval in Canada last year and pursuing approvals in the European Union and other regions, though it recently withdrew its UK application for procedural reasons. The company is also developing Amtagvi for endometrial cancer and advancing other pipeline candidates. However, significant risks remain, including the complexity and cost of manufacturing and administering its therapies, which could challenge profitability, and the potential for clinical or regulatory setbacks.

Iovance Biotherapeutics is favored over Heartflow as the better risk-adjusted healthcare stock for 2026, based on its lower price-to-sales ratio. Heartflow, which relies on its FFR CT Analysis product for 98% of its roughly $176 million in fiscal 2025 revenue, posted a net loss of $116.8 million and negative free cash flow of nearly $59 million. Iovance generated $263.5 million in revenue, a 60.6% increase, but recorded a deeper net loss of about $391 million and negative free cash flow of $336.2 million. Both companies carry a debt-to-equity ratio of approximately 0.1x and are not expected to turn free cash flow positive until 2028. Heartflow faces concentration risk and a proposed 15% Medicare reimbursement cut, while Iovance manages an accumulated deficit of $2.9 billion and complex manufacturing challenges.

Iovance Biotherapeutics shares jumped 9.36 percent to close at $4.44 after the company secured conditional approval from Australia’s Therapeutic Goods Administration for its melanoma therapy Amtagvi. The approval marks the third marketing authorization for the tumor-derived autologous T-cell immunotherapy, following earlier nods in the US and Canada. Australia has the highest rate of melanoma globally, with an estimated 17,000 new cases diagnosed each year and more than 1,500 deaths annually. President and CEO Frederick Vogt said the company is in the process of authorizing its first Australian treatment center as it expands into additional markets with a high prevalence of advanced melanoma.